EcoDrugPlus

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSAPOG00000023753
Gene Symbol: LOC110954188
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSAPOG00000022322
Gene Symbol: LOC110957121
3 Cross references
200 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSAPOG00000009362
Gene Symbol: LOC110965747
3 Cross references
194 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSAPOG00000008537
Gene Symbol: LOC110961051
4 Cross references
201 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSAPOG00000001720
Gene Symbol: LOC110962971
3 Cross references
195 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSAPOG00000005300
Gene Symbol: LOC110968840
2 Cross references
186 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSAPOG00000023268
Gene Symbol: LOC110956564
3 Cross references
208 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSAPOG00000017503
Gene Symbol: NPY2R
1 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSAPOG00000013058
Gene Symbol: LOC110972813
2 Cross references
144 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSAPOG00000018544
Gene Symbol: LOC110950233
3 Cross references
172 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSAPOG00000023779
Gene Symbol: LOC110968389
2 Cross references
144 Possible Orthologues:

Neuropeptide Y Receptor Type 4-Like

Ensembl ID : ENSAPOG00000003352
Gene Symbol: LOC110958659
3 Cross references
137 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).